We are entering the era of the China-based biotechnology firm. Roughly half the drug development deals signed by big US and European pharmaceutical companies this year are on track to involve a Chinese biotech partner, according to Vision Lifesciences. The reason for all these deals? The innovative molecules being discovered by scientists in China.
The rise of China and other Asian countries as drug discovery powerhouses was the subject of a panel discussion at ANVF Innovation 2026, a conference recently hosted in Singapore by the Chinese business publication Caixin. A C&EN editor moderated the panel.
